Volinanserin

Volinanserin
Clinical data
Other names	MDL-100,907; MDL-100907; MDL100907; M100907; M-100907; M-100,907
Routes of; administration	Oral
Drug class	Serotonin 5-HT2A receptor antagonist
ATC code	None;
Pharmacokinetic data
Onset of action	TmaxTooltip Time to peak levels: 1–2.5 hours
Elimination half-life	6.6 hours (range 4.5–9.8 hours)
Identifiers
	IUPAC name (R)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]-4-piperidyl]methanol;
CAS Number	139290-65-6;
PubChem CID	5311271;
IUPHAR/BPS	185;
ChemSpider	4470782;
UNII	EW71EE171J;
ChEMBL	ChEMBL74355;
CompTox Dashboard (EPA)	DTXSID6047363 ;
ECHA InfoCard	100.123.797
Chemical and physical data
Formula	C22H28FNO3
Molar mass	373.468 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC=CC(=C1OC)[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O;
	InChI InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1; Key:HXTGXYRHXAGCFP-OAQYLSRUSA-N;

Volinanserin (INNTooltip International Nonproprietary Name; developmental code MDL-100,907) is a highly selective 5-HT_2A receptor antagonist that is frequently used in scientific research to investigate the function of the 5-HT_2A receptor. It was also tested in clinical trials as a potential antipsychotic, antidepressant, and treatment for insomnia but was never marketed. The drug reached phase 3 trials for schizophrenia and insomnia prior to the discontinuation of its development in the late 2000s. It is taken orally.